vs
Side-by-side financial comparison of bioAffinity Technologies, Inc. (BIAF) and NSTS Bancorp, Inc. (NSTS). Click either name above to swap in a different company.
NSTS Bancorp, Inc. is the larger business by last-quarter revenue ($2.5M vs $1.6M, roughly 1.6× bioAffinity Technologies, Inc.). NSTS Bancorp, Inc. runs the higher net margin — 214.3% vs -197.0%, a 411.3% gap on every dollar of revenue. On growth, NSTS Bancorp, Inc. posted the faster year-over-year revenue change (3.0% vs -27.8%). NSTS Bancorp, Inc. produced more free cash flow last quarter ($3.9M vs $-2.6M). Over the past eight quarters, NSTS Bancorp, Inc.'s revenue compounded faster (11.7% CAGR vs -18.6%).
bioAffinity Technologies, Inc. is a clinical-stage biotechnology firm focused on developing non-invasive in vitro diagnostic tests for early detection of cancer and respiratory diseases. It serves global healthcare markets, with a core mission to deliver accessible, high-accuracy diagnostic solutions that improve patient outcomes and reduce overall healthcare system costs.
NSTS Bancorp, Inc. is a U.S.-based bank holding company. It offers a comprehensive suite of retail and commercial banking products and services, including deposit accounts, personal loans, commercial loans, and wealth management solutions, primarily serving individual consumers and small-to-medium enterprises in its regional operating areas.
BIAF vs NSTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $2.5M |
| Net Profit | $-3.1M | $135.0K |
| Gross Margin | — | — |
| Operating Margin | -196.9% | — |
| Net Margin | -197.0% | 214.3% |
| Revenue YoY | -27.8% | 3.0% |
| Net Profit YoY | -5.7% | 393.5% |
| EPS (diluted) | $-3.59 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $2.5M | ||
| Q3 25 | $1.4M | $2.5M | ||
| Q2 25 | $1.3M | $2.5M | ||
| Q1 25 | $1.9M | $2.2M | ||
| Q4 24 | $2.2M | $2.4M | ||
| Q3 24 | $2.4M | $2.3M | ||
| Q2 24 | $2.4M | $2.3M | ||
| Q1 24 | $2.4M | $2.0M |
| Q4 25 | $-3.1M | $135.0K | ||
| Q3 25 | $-5.1M | $65.0K | ||
| Q2 25 | $-4.1M | $-258.0K | ||
| Q1 25 | $-2.7M | $-328.0K | ||
| Q4 24 | $-3.0M | $-46.0K | ||
| Q3 24 | $-2.0M | $-171.0K | ||
| Q2 24 | $-2.1M | $-326.0K | ||
| Q1 24 | $-2.0M | $-246.0K |
| Q4 25 | -196.9% | — | ||
| Q3 25 | -158.6% | 2.6% | ||
| Q2 25 | -198.2% | -10.1% | ||
| Q1 25 | -141.7% | -15.2% | ||
| Q4 24 | -133.5% | -71.9% | ||
| Q3 24 | -84.0% | -7.6% | ||
| Q2 24 | -87.1% | -14.2% | ||
| Q1 24 | -80.8% | -12.2% |
| Q4 25 | -197.0% | 214.3% | ||
| Q3 25 | -349.3% | 2.6% | ||
| Q2 25 | -319.9% | -10.1% | ||
| Q1 25 | -143.5% | -15.2% | ||
| Q4 24 | -134.4% | -71.9% | ||
| Q3 24 | -85.1% | -7.6% | ||
| Q2 24 | -88.0% | -14.2% | ||
| Q1 24 | -81.5% | -12.2% |
| Q4 25 | $-3.59 | — | ||
| Q3 25 | $-4.74 | $0.01 | ||
| Q2 25 | $-0.17 | — | ||
| Q1 25 | $-0.16 | — | ||
| Q4 24 | $-17.27 | — | ||
| Q3 24 | $-4.84 | $-0.03 | ||
| Q2 24 | $-0.19 | — | ||
| Q1 24 | $-0.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.4M | $34.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.3M | $80.0M |
| Total Assets | $11.0M | $266.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.4M | $34.0M | ||
| Q3 25 | $7.7M | $34.1M | ||
| Q2 25 | $802.8K | $47.5M | ||
| Q1 25 | $444.7K | $57.5M | ||
| Q4 24 | $1.1M | $53.5M | ||
| Q3 24 | $756.6K | $34.6M | ||
| Q2 24 | $801.3K | $32.4M | ||
| Q1 24 | $2.5M | $36.4M |
| Q4 25 | $7.3M | $80.0M | ||
| Q3 25 | $8.9M | $78.9M | ||
| Q2 25 | $-2.1M | $77.8M | ||
| Q1 25 | $1.4M | $77.5M | ||
| Q4 24 | $2.6M | $76.5M | ||
| Q3 24 | $3.1M | $78.4M | ||
| Q2 24 | $3.4M | $76.5M | ||
| Q1 24 | $5.3M | $77.0M |
| Q4 25 | $11.0M | $266.6M | ||
| Q3 25 | $11.5M | $269.8M | ||
| Q2 25 | $4.8M | $276.0M | ||
| Q1 25 | $5.5M | $282.7M | ||
| Q4 24 | $6.5M | $278.7M | ||
| Q3 24 | $6.6M | $268.4M | ||
| Q2 24 | $6.7M | $265.9M | ||
| Q1 24 | $8.0M | $265.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.6M | $4.1M |
| Free Cash FlowOCF − Capex | $-2.6M | $3.9M |
| FCF MarginFCF / Revenue | -160.7% | 156.9% |
| Capex IntensityCapex / Revenue | 0.0% | 4.1% |
| Cash ConversionOCF / Net Profit | — | 30.01× |
| TTM Free Cash FlowTrailing 4 quarters | $-9.4M | $4.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.6M | $4.1M | ||
| Q3 25 | $-2.5M | $2.9M | ||
| Q2 25 | $-2.6M | $655.0K | ||
| Q1 25 | $-1.6M | $-2.7M | ||
| Q4 24 | $-1.7M | $9.4M | ||
| Q3 24 | $-1.7M | $1.6M | ||
| Q2 24 | $-1.5M | $-1.6M | ||
| Q1 24 | $-2.3M | $92.0K |
| Q4 25 | $-2.6M | $3.9M | ||
| Q3 25 | $-2.5M | $2.9M | ||
| Q2 25 | $-2.7M | $616.0K | ||
| Q1 25 | $-1.7M | $-2.7M | ||
| Q4 24 | $-1.7M | $9.1M | ||
| Q3 24 | $-1.7M | $1.6M | ||
| Q2 24 | $-1.6M | $-1.7M | ||
| Q1 24 | $-2.4M | $76.0K |
| Q4 25 | -160.7% | 156.9% | ||
| Q3 25 | -171.8% | 113.9% | ||
| Q2 25 | -209.6% | 24.2% | ||
| Q1 25 | -91.3% | -126.1% | ||
| Q4 24 | -76.0% | 373.1% | ||
| Q3 24 | -73.1% | 69.3% | ||
| Q2 24 | -65.1% | -76.4% | ||
| Q1 24 | -99.2% | 3.8% |
| Q4 25 | 0.0% | 4.1% | ||
| Q3 25 | 0.3% | 0.1% | ||
| Q2 25 | 1.1% | 1.5% | ||
| Q1 25 | 2.7% | 2.5% | ||
| Q4 24 | 0.0% | 13.1% | ||
| Q3 24 | 0.4% | 2.3% | ||
| Q2 24 | 1.2% | 5.1% | ||
| Q1 24 | 1.7% | 0.8% |
| Q4 25 | — | 30.01× | ||
| Q3 25 | — | 44.03× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
